WEBINAR: Biomanufacturing of Pluripotent Stem Cells and Their Differentiated Progenies in Integrated Bioprocesses

Cell therapy manufacturing is a new discipline where production of adult and pluripotent stem cell types are required for cell therapies. Several hundreds of clinical trials with adult mesenchymal stem cells for therapies such as auto-immune diseases, bone, cartilage repair and stroke are looking promising. For the pluripotent stem cell therapies, retinal pigment epithelial cells, pancreatic islet progenitors and neurons are being applied for treating blindness, diabetes and Parkinson’s disease in early stage clinical trials.

September 10, 2018

Biomanufacturing of Pluripotent Stem Cells and Their Differentiated Progenies in Integrated Bioprocesses​
Monday, October 22, 2018
9:00 AM EST


The Bioprocessing Technology Institute has developed advanced capabilities in microcarrier based cultures for the production of human pluripotent stem cells (hPSC) which are scalable and provides extensive control in bioreactors to achieve high cell densities by volumetric scale up. This microcarrier based technology has been refined to cover the entire value chain of reprogramming donor blood to human induced pluripotent stem cells (hiPSC), selecting for high quality clones for banking, scaling the production of hiPSC in bioreactors and differentiating them to functional cell types such as cardiomyocytes and the blood lineages. We demonstrate how microcarrier technology combined with induction of the Wnt signaling pathways provides an improved yield of mesoderm derivatives compared to the conventional embryoid body approach, yielding high densities of cardiomyocytes in a 1 litre bioreactor. This technology has also been applied for expansion of extremely high yields of erythroblasts and red blood greater than 10e7 cells/ml in a completely integrated fashion. This streamlined process has been demonstrated for 10 hiPSC donor lines with O negative, Rhesus negative phenotype and forms the basis for building a manufacturing platform for off the shelf blood products.

This moderated presentation will cover:

  • An integrated bioprocess for reprogramming, expansion and differentiation of pluripotent stem cells
  • Examples of producing high density cultures of cardiomyocytes and red blood cells
  • Opportunities for collaboration


About the Presenter: 

Steve Oh is the director of stem cell bioprocessing and institute professor/scientist of the Bioprocessing Technology Institute (BTI) at the Agency for Science Technology and Research (A*STAR) and an authority in integrated stem cell bioprocessing for the manufacture of human pluripotent/embryonic and adult mesenchymal stem cells for cell-based therapies. Key recent achievements include ultra-high density production of pluripotent stem cells, cardiomyocytes, neuroprogenitors and red blood cells in suspension bioreactors. In the mesenchymal stem cell (MSC) area, methods of producing high quality MSCs, and primed towards cartilage and bone repair have been achieved. He has 100+ publications and 40+ patents in stem cells therapies and bioprocessing.

Steve was the International Society of Cellular Therapies (ISCT) Co-Vice President (Asia) from 2015-2017, and led the planning of the sessions for commercialisation of cell therapies for the Silver Jubilee (25 years) ISCT meeting at Suntec City, Singapore, in 2016. He is also the current vice president of the Singapore Stem Cell Society and holds an adjunct professorship at the School of Biological Science and Engineering, Nanyang Technological University.

Steve has founded two stem cell companies, Brilliant Research and Veristem and is a veteran of 28 years in the biotech industry. Steve has also written two award-winning books for general education of citizens of the world on the potential of stem cells for therapies entitled: “Sensational Stem Cells! How to cure Medical complications” and “The Authorities.”